引用本文
  •    [点击复制]
  •    [点击复制]
PDF HTML全文阅读
本文已被:浏览 863次   下载 1021 本文二维码信息
码上扫一扫!
软坚通脉颗粒对 DLAO 患者部分炎症因子的影响
徐丽英,曹烨民,李土明,钟萍,杨建飞
0
上海中医药大学附属上海市中西医结合医院脉管科(上海 200082);上海中医药大学附属上海市中西医结合医院脑病科(上海 200082)
摘要:
目的:探讨软坚通脉颗粒对痰湿证 DLAO 患者的临床疗效及其部分炎症的影响。方法:选取 69 例 DLAO 一期或二期的痰湿证患者,随机分为治疗组和对照组。对照组(n=35)给予标准抗凝、稳定斑块、扩血管等治疗;治疗组(n=34) 在对照组基础上加服软坚通脉颗粒,疗程为 4 周。观察两组治疗前后血清 APN、CysC、hs-CRP、IL-6、PCT 水平,评价两组治疗前后中医证候评分、临床症状积分的疗效。结果:治疗后治疗组中医证候评分(97% vs 51%,P<0.01)及临床症状评分(97% vs 80%,P<0.05)有效率均明显高于对照组。治疗组治疗前后血清 APN 分别为(4.77±0.41)μg/mL 和(5.16±0.48)μg/mL ;CysC 分别为(1.33±0.45)mg/L 和(1.02±0.26)mg/L ;hs-CRP 分别为(6.71±4.31)mg/L 和(3.43±2.77)mg/L ;IL-6 分别为(12.14±8.53)pg/mL 和(6.21±4.83)pg/mL ;治疗组较对照组的血清 APN 显著升高(P<0.05),血清 CysC、hs-CRP、IL-6 显著降低(P<0.05);两组血清 PCT 在治疗后无统计学差异(P>0.05)。结论:软坚通脉颗粒可上调痰湿证 DLAO 患者的血清 APN 水平,抑制血清 CysC 水平、hs-CRP、IL-6 水平,具有一定的抗炎、抗动脉粥样硬化作用。
关键词:  糖尿病肢体动脉闭塞症  软坚通脉颗粒  痰湿证  炎症因子
DOI:10.3969/j.issn.1007-6948.2019.05.026
基金项目:上海市科学技术委员会科研计划项目(17401933200)
Effect of Ruanjian Tongmai Granule on Some Inflammatory Factors in Diabetic Limb Arterial Occlusion
XU Li-ying,CAO Ye-min,LI Tu-ming
Department of Circulatory, Shanghai TCM-Integrated Hospital, Af?liated to Shanghai University of Chinese Medicine, Shanghai (20082), China
Abstract:
Objective To investigate the clinical effect of Ruanjian Tongmai Granule on DLAO patients with phlegm-dampness syndrome and its inflammatory mechanism. Methods Sixty-nine DLAO patients with phlegm-dampness syndrome were randomly divided into treatment group and control group. The patients in control group (n=35) were given standard anticoagulation, stable plaque, vasodilation and other treatments; the patients in treatment group (n=34) were given Ruanjian Tongmai Granule on the basis of the control group, and the course of treatment was four weeks. The levels of serum APN, CysC, hs-CRP, IL-6 and PCT were observed before and after treatment in two groups. The scores of TCM syndromes and clinical symptoms were evaluated before and after treatment. Results After treatment, the effective rates of TCM syndrome score (97% vs 51%, P<0.01) and clinical symptom score (97% vs 80%, P<0.05) in the treatment group were signi?cantly higher than those in the control group. The serum APN of the treatment group before and after treatment was (4.77 ±0.41) μg/mL and (5.16 ±0.48) μg/mL, CysC was (1.33±0.45) mg/L and (1.02 ±0.26) mg/L, hs-CRP was (6.71±4.31)mg/L and (3.43±2.77) mg/L, and IL-6 was (12.14±8.53) pg/mL and (6.21±4.83) pg/mL.The serum APN levels in the treatment group were signi?cantly higher than those in the control group (P<0.05), the serum CysC, hs-CRP and IL-6 levels in the treatment group were signi?cantly lower than those in the control group (P<0.05), and the serum PCT levels were not signi?cantly different between the two groups (P>0.05). Conclusion Ruanjian Tongmai Granule can up-regulate serum APN levels, inhibit serum CysC, hs-CRP and IL-6 levels in DLAO patients with phlegm-dampness syndrome, and has certain anti-in?ammatory and anti-atherosclerosis effects.
Key words:  Diabetic limb arterial occlusion  Ruanjian Tongmai Granule  phlegm-dampness syndrome  in?ammatory factor

用微信扫一扫

用微信扫一扫